Teva Pharmaceutical Industries

20 stories about Teva Pharmaceutical Industries
קור שולץ מנכ"ל טבע 9.11.19

Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth

08.11.20|Sophie Shulman
CEO Kare Schultz managed over the past three years to keep the boat steady and lessen its debt, but slow growth won’t satisfy investors
קורונה נשיא סין שי ג'ינפינג  ב בייג'ינג 10.2.20

For foreign companies, understanding China’s annual plans is critical

12.10.20|Tslil Kleiman
Chinese governmental programs not only define what is “forbidden” and “allowed,” but also determine to which regions and industries investments will be directed, and which projects will be given priority
ד"ר דנה בר און Dr. Dana Bar-on

Teva is recruiting Israeli academia to help produce its next breakthrough drug

You reap what you sow: The pharmaceutical giant is partnering up with researchers to try and find the next Copaxone
אסף וייס  מנכ"ל עמותת יוניסטרים

A renaissance of entrepreneurship and innovation is our chance to withstand the Covid-19 challenge

23.08.20|Assaf Weiss
The global crisis presents us with a load of new opportunities for online activities in the fields of commerce, education, work, and leisure
מטה טבע פתח תקווה

Teva Gets Fresh Cash, Fresh Woes

04.02.18|Dror Reich
After the troubled drugmaker finalized two deals that will enable it to repay some of its debt, S&P placed it on CreditWatch negative on Friday
מטה טבע פתח תקווה

Following U.S. Bribe Settlement, Teva to Pay $22 Million Fine in Israel

15.01.18|Tomer Ganon
Yesterday, the Israeli state attorney settled a suit against the company. In 2016, Teva agreed to pay $519 million to settle anti-bribery violations in the U.S.
עובדי מפעל טבע נתניה

Moody’s Downgrades Teva Bond Rating to “Junk”

14.01.18|Lilach Baumer
The credit rating agency is following is the steps of Fitch, which did the same in November. Of the “big three,” only S&P Global still rates Teva as investment grade
מוסף 16.5 הון אנושי סול ג'יי בארר  Sol J. Barer

After Announcing Restructuring Plan, Teva's Board of Directors Takes Paycut

11.01.18|Lilach Baumer
In December, the generic drugmaker announced a plan to let go 14,000 employees
מנכ"ל טבע החדש קור שולץ 2

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer
The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
עובדי טבע חוסמים את אזור הכניסה ל ירושלים

Teva CEO to Netanyahu: Layoffs will Proceed as Planned

19.12.17|Omri Milman
In a statement, the company said it rejects the Israeli government’s appeal to withdraw cutback plans
default image

Following Restructuring Announcements, Teva Reinstated as Israel’s Biggest Company

18.12.17|Lilach Baumer
Teva's stock jumped 18.7% on the New York Stock Exchange between Thursday market opening and Friday market close. Israeli Prime Minister Benjamin Netanyahu is expected to meet with CEO Kåre Schultz Tuesday
מנכ"ל טבע החדש קור שולץ

Teva Might Have Been Better Off as a Smaller Company, new CEO Says

17.12.17|Dror Reich
The generic drugs powerhouse is now carrying a $34.7 billion debt—a result of a $40.5 acquisition of Actavis. New CEO Kåre Schultz presented a detailed restructuring plan on Thursday
אחרי ה שביתה נתב"ג טבע פיטורים טיסות טרמינל

Tel Aviv Airport, Stock Market Open as Solidarity Strike Ends

17.12.17|Lior Gutman, Omri Milman and Micky Grunfeld
Israel’s largest labor union called for a half-day strike on Thursday, in support of Teva employees
פסקל סוריו מנכ"ל AstraZeneca

Once Future CEO Could have Taken Teva on a Different Path

14.12.17|Lilach Baumer, Golan Hazani, and Orr Hirschauge
AstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
מנכ"ל טבע החדש קור שולץ 2

Teva to Cut Around Half of Israeli Workforce, Outsource Operations

13.12.17|Dror Reich
An internal document reviewed by Calcalist reveals the troubled drugmaker's detailed domestic cost-cutting plans
מפעל טבע טק ב רמת חובב

Teva to Cut Jobs, Shut Down Some Israeli Operations

13.12.17|Dror Reich and Sefi Krupsky
On Thursday, the troubled drugmaker is expected to unveil its cutback plan. At its center is extensive layoffs and the reorganization and divestment of non-core assets
יצחק פטרבורג

Former Chairman Yitzhak Peterburg Leaves Teva

13.12.17|Lilach Baumer
Mr. Peterburg was the troubled drugmaker's interim CEO between February and November 1, when Kåre Schultz took helm
מנכ"ל טבע החדש קור שולץ 1

Teva to Unveil Strategic Plan, Layoffs Thursday

12.12.17|Dror Reich
Last month the debt-riddled drug maker announced a rehabilitation plan amidst rumors of upcoming employee cuts
מפעל טבע נתניה

Teva’s Stock Jumps Following Report on Planned Cuts

10.12.17|Dror Reich and Lilach Baumer
On Friday, Bloomberg reported that Teva might be slashing as many as 10,000 jobs, citing sources. Last month, Calcalist reported Teva is planning to cut over 4,000 jobs in the U.S. and Israel
חברת ה תרופות טבע Teva

Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker

30.11.17|Anat Rouah
Tel Aviv-based capital investment firm Tulip Capital is threatening derivative action against Teva, saying the company's huge debt load renders its dividends unlawful